Prospects for combining targeted and conventional cancer therapy with immunotherapy

By P. Gotwals, S. Cameron, D. Cipolletta, V. Cremasco, A. Crystal, B. Hewes, Britta Mueller, S. Quaratino, C. Sabatos-Peyton, L. Petruzzelli and 2 more. Nature Reviews. Cancer, 2017

862 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/6de74d849114bf04cd2e703b9c02881d07ec53b7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

SynergyFinder 2.0: visual analytics of multi-drug combination synergies (2020, background): “As a result, higher-order combination therapies involving three or more drugs have been approved or investigated for multiple diseases (e.g. cancers, HIV and tuberculosis) (1,3,5).”
Genetics and biology of prostate cancer (2018, background): “…patient’s immune system is lacking; the efficacy, toxicity, and tolerability associated with combination therapies need to be determined through optimization of dosing regimens and sequencing, and approaches for prioritizing various combination therapies need to be developed (Gotwals et al. 2017).”
Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “…and nivolumab), anti-PD-L1 (MPDL3280A), and anti-CTLA4 (ipilimumab) has had remarkable success enhancing the effector anti-tumor response in different malignancies (Gotwals et al. 2017), especially in melanoma and lung cancer (Hamid et al. 2013; Herbst et al. 2014; Topalian et al. 2015).”
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022, background): “Chemotherapy modifying the TME Chemotherapy retards tumor growth mainly by arresting cell cycle, inhibiting DNA replication, disturbing cell metabolism, or suppressing microtubule assembly [32].”
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review (2018, background): “IL‐2 also promotes differentiation of CTLs into their effector cells (Borst et al., 2018) and induces polarization of macrophages toward their antitumor M1 phenotype (Guerriero, 2018).”
Nanomedicine in cancer therapy (2023, background): “162 For example, by means of selective enzymatic cleavage, an intact antibody can be cleaved into several different fragments including antigen-binding fragment (Fab), Fab ’ , and F(ab ’ ) 2 .”
Tumor Targeting via EPR: Strategies to Enhance Patient Responses (2018, background): “Recently, anticancer therapy focusing on combining immunotherapy with nanomedicines are investigated to tackle the challenges associated with the conventional approach, by decreasing immune-related adverse events while enhanced efficacy [174,175].”